Cite
MLA Citation
M. Toulmonde et al.. “31LBA MOST – My Own Specific Therapy – A multicenter, randomized, open-label, phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors: preliminary results from the everolimus and sorafenib cohorts.” European journal of cancer, vol. 51, n.d., pp. S725–S726. http://access.bl.uk/ark:/81055/vdc_100030687872.0x000055